Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (Q24246148)

Europe PubMed Central

title

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (English)

0 references

author

Astrid Austvoll-Dahlgren

2

0 references

Andrew D. Oxman

4

object named as

Andrew D Oxman

0 references

author name string

Morten Aaserud

1

0 references

Jan Peter Kösters

3

0 references

Craig Ramsay

5

0 references

Heidrun Sturm

Cochrane Database of Systematic Reviews

6

0 references

publication date

19 April 2006

0 references

published in

0 references

cites work

Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Do pharmaceutical prices respond to potential patient out-of-pocket expenses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Prescription duration after drug copay changes in older people: methodological aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Lowering generic drug prices: less regulation equals more competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

The German experience in reference pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Pharmaceutical policies: effects on rational drug use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Interventions to improve antibiotic prescribing practices for hospital inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Pharmaceutical reference prices. How do they work in practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Mass media interventions: effects on health services utilisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Intervention research in rational use of drugs: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

What is required to evaluate the impact of pharmaceutical reference pricing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Do national medicinal drug policies and essential drug programs improve drug use?: a review of experiences in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

A critical analysis of studies of state drug reimbursement policies: research in need of discipline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

7 January 2021

Substitution laws, insurance coverage, and generic drug use

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

7 January 2021

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

7 January 2021

Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

7 January 2021

Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

7 January 2021

Do Pharmaceutical Prices Respond to Insurance?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005979

7 January 2021

10.1002/14651858.CD005979

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3191275

OpenCitations bibliographic resource ID

3191275

1 reference